CI
CING.US Cingulate Inc
- Market cap
- USD 62.5M
- P/E
- -
- P/B
- 2.77x
- ROE
- -49.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CING.US undervalued?
Graham numberThe Graham number of Cingulate Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cingulate Inc fundamental analysis
No fundamental analysis for Cingulate Inc yet.
Cingulate Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the trea…
Full company profileCingulate Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cingulate Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -179K | -842K | -808K | -622K | -583K | -653K | -541K | - |
| Operating Income | -11.6M | -7.08M | -20.7M | -17.5M | -22.8M | -15.6M | -19.9M | - |
| EBITDA | -11.5M | -6.42M | -20.0M | -17.1M | -22.2M | -15.0M | -19.4M | - |
| Net Income | -11.5M | -7.18M | -20.7M | -17.9M | -23.5M | -16.6M | -22.4M | -10.3B |
| EPS | -8.17 | -5.08 | -15 | -13 | -10 | -4.34 | -4.13 | -710 |
| Balance Sheet | ||||||||
| Total Assets | 5.28M | 5.79M | 22.9M | 11.4M | 3.49M | 14.9M | 15.1M | 28.2B |
| Total Liabilities | 4.66M | 4.50M | 2.04M | 7.52M | 10.4M | 7.41M | 12.6M | 899M |
| Shareholders' Equity | 616K | 1.29M | 20.8M | 3.88M | -6.87M | 7.46M | 2.51M | 20.8B |
| Cash & Short-term Investments | 437K | 1.20M | 16.5M | 5.36M | 52.4K | 12.2M | 11.0M | 23.2B |
| Total Debt | 2.09M | 2.05M | 1.18M | 5.87M | 3.51M | 5.10M | 8.79M | 1.16B |
| Cash Flow | ||||||||
| Operating Cash Flow | -9.53M | -6.81M | -10.4M | -15.9M | -15.0M | -18.5M | -17.2M | -26.9B |
| Capital Expenditure | 1.02M | 402K | 815K | 153K | 224K | 212K | 162K | 282M |
| Free Cash Flow | -10.5M | -7.21M | -11.2M | -16.0M | -15.3M | -18.7M | -17.4M | -27.2B |
| Ratios | ||||||||
| ROE | -1,874.8% | -555.8% | -99.4% | -459.8% | - | -222.1% | -894.8% | -49.7% |
| ROA | -218.6% | -124.1% | -90.5% | -156.5% | -674.1% | -111.4% | -148.9% | -36.7% |
| Debt to Equity | 3.39x | 1.58x | 0.06x | 1.51x | - | 0.68x | 3.50x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cingulate Inc dividends
Cingulate Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:12 on Aug 9, 2024.
Who owns Cingulate Inc
- Insiders 28.75%
- Institutions 16.41%
- Public & others 54.84%
- Shares outstanding 14.5M
- Free float 14.2M
Top funds holding CING.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 395K | 2.71% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 71.1K | 0.49% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 27.9K | 0.19% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 22.5K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 21.4K | 0.15% | 0.00% | Sep 2026 |
| Abante Quant Value FI | 17.8K | 0.12% | 0.00% | Aug 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 10.2K | 0.07% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 5.68K | 0.04% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 4.74K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 1.87K | 0.01% | 0.00% | Sep 2026 |
| JHVIT Total Stock Market Index I | 246.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding CING.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 571K | 3.93% | +84.77% | Jun 2026 |
| Chicago Partners Investment Group LLC | 188K | 1.30% | +904.95% | Jun 2026 |
| Kestra Advisory Services, LLC | 152K | 1.04% | +8.21% | Jun 2026 |
| Geode Capital Management, LLC | 145K | 0.99% | +42.68% | Jun 2026 |
| Renaissance Technologies Corp | 128K | 0.88% | +299.84% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 79.2K | 0.54% | +58.09% | Jun 2026 |
| BlackRock Inc | 53.1K | 0.37% | +128.33% | Jun 2026 |
| BCV Asset Management Inc. | 51.2K | 0.35% | 0.00% | Jun 2026 |
| State Street Corp | 47.9K | 0.33% | +73.58% | Jun 2026 |
| Northern Trust Corp | 35.1K | 0.24% | +57.69% | Jun 2026 |
| Quantum Private Wealth, LLC | 30.0K | 0.21% | 0.00% | Sep 2026 |
| Prospera Financial Services Inc | 29.9K | 0.21% | +37.16% | Jun 2026 |
| Jane Street Group LLC | 28.9K | 0.20% | -68.22% | Jun 2026 |
| UBS Group AG | 25.9K | 0.18% | +135.18% | Jun 2026 |
| Mariner Wealth Advisors LLC | 21.3K | 0.15% | +64.59% | Jun 2026 |
| XTX Topco Ltd | 20.8K | 0.14% | -61.09% | Jun 2026 |
| Jump Financial LLC | 14.6K | 0.10% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 12.1K | 0.08% | -56.20% | Jun 2026 |
| Pks Advisory Services, LLC | 11.5K | 0.08% | 0.00% | Jun 2026 |
| Vanguard Global Advisers, LLC | 4.74K | 0.03% | 0.00% | Jun 2026 |
Cingulate Inc company profile
- Company name
- Cingulate Inc
- Ticker
- CING.US
- Exchange
- USA Stocks
- Listed since
- Dec 8, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 1901 West 47th Place, Kansas City, KS, United States, 66205
- Phone
- 913 942 2300
- Website
- cingulate.com
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc management
6- Dr. Shane J. Schaffer Pharm.D.Co-Founder, CEO & Chairman of the Board · born 1975
- Dr. Matthew N. Brams M.D.Co-Founder, Executive VP & Chief Medical Officer · born 1964
- Ms. Jennifer L. Callahan CPAExecutive VP, CFO & Secretary · born 1971
- Dr. Raul R. Silva M.D.Co-Founder, Executive VP & Chief Science Officer · born 1958
- Mr. Thomas DaltonVice President of Investor & Public Relations
- Mr. Downey Bryan WadeExecutive VP & Chief Commercial Officer · born 1972